newsfilter
← Latest News
Business Wire·

Ironwood Pharmaceuticals Reports Second Quarter 2024 Results

– LINZESS® (linaclotide) EUTRx prescription demand growth of 11% year-over-year – – Plans to pursue apraglutide rolling NDA review; expects to complete submission in the first quarter of 2025 – – On track to